AmCad BioMed

AmCad BioMed, founded in 2008 and listed on the Taipei Exchange (Ticker: 4188), specializes in AI-powered ultrasound solutions that support early and accurate diagnosis.

​

We develop patented ultrasound AI technologies that help doctors detect diseases faster and interpret images with greater consistency.

​

Headquartered in Taiwan, AmCad holds multiple FDA and CE certifications and continues to advance medical imaging through real-world innovation.

​

We are committed to responsible growth, with strong investments in R&D and a focus on ESG principles across our operations.